CN107522777B - 用于预防或治疗流感病毒的多肽、免疫原性偶联物及用途 - Google Patents
用于预防或治疗流感病毒的多肽、免疫原性偶联物及用途 Download PDFInfo
- Publication number
- CN107522777B CN107522777B CN201710824011.5A CN201710824011A CN107522777B CN 107522777 B CN107522777 B CN 107522777B CN 201710824011 A CN201710824011 A CN 201710824011A CN 107522777 B CN107522777 B CN 107522777B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- influenza
- protein
- crm197
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
动物品系 | 性别 | 体重 | 周龄 | 数量(只) |
Balb/c小鼠 | 雌性 | 18~22g | 6~8周 | 10 |
动物品系 | 性别 | 体重 | 周龄 | 数量(只) |
Balb/c小鼠 | 雌性 | 18~22g | 6~8周 | 80 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710824011.5A CN107522777B (zh) | 2017-09-13 | 2017-09-13 | 用于预防或治疗流感病毒的多肽、免疫原性偶联物及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710824011.5A CN107522777B (zh) | 2017-09-13 | 2017-09-13 | 用于预防或治疗流感病毒的多肽、免疫原性偶联物及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107522777A CN107522777A (zh) | 2017-12-29 |
CN107522777B true CN107522777B (zh) | 2021-06-11 |
Family
ID=60736684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710824011.5A Active CN107522777B (zh) | 2017-09-13 | 2017-09-13 | 用于预防或治疗流感病毒的多肽、免疫原性偶联物及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107522777B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114057848B (zh) * | 2020-08-07 | 2023-11-21 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057847B (zh) * | 2020-08-07 | 2024-04-02 | 清华大学 | 一种预防新型冠状病毒covid-19的多肽、免疫原性偶联物及其用途 |
CN114057844A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1838967A (zh) * | 2002-12-10 | 2006-09-27 | 洛伦蒂斯有限公司 | 稳定的免疫原性HBc嵌合体颗粒 |
CN101080239A (zh) * | 2003-02-21 | 2007-11-28 | 洛伦蒂斯有限公司 | 作为慢性肝炎治疗性疫苗的稳定化HBc嵌合体颗粒 |
CN101309699A (zh) * | 2005-08-31 | 2008-11-19 | 塞尔德克斯医疗有限公司 | 稳定化的病毒样颗粒和表位展示系统 |
CN102807621A (zh) * | 2011-06-01 | 2012-12-05 | 厦门大学 | 包含白喉毒素无毒突变体crm197或其片段的融合蛋白 |
-
2017
- 2017-09-13 CN CN201710824011.5A patent/CN107522777B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1838967A (zh) * | 2002-12-10 | 2006-09-27 | 洛伦蒂斯有限公司 | 稳定的免疫原性HBc嵌合体颗粒 |
CN101080239A (zh) * | 2003-02-21 | 2007-11-28 | 洛伦蒂斯有限公司 | 作为慢性肝炎治疗性疫苗的稳定化HBc嵌合体颗粒 |
CN101309699A (zh) * | 2005-08-31 | 2008-11-19 | 塞尔德克斯医疗有限公司 | 稳定化的病毒样颗粒和表位展示系统 |
CN102807621A (zh) * | 2011-06-01 | 2012-12-05 | 厦门大学 | 包含白喉毒素无毒突变体crm197或其片段的融合蛋白 |
Non-Patent Citations (3)
Title |
---|
Immunogenicity of Haemophilus influenzae-diphtheria CRM197 protein conjugate vaccine (HbOC) in Libyan infants;M. Hadida 等;《Tropical Medicine and International Health》;19980228;第3卷(第2期);第95-99页 * |
Universal vaccines: shifting to one for many or shooting too high too soon!;MAWIEH HAMAD;《APMIS》;20111231;第119卷;第565-573页 * |
流感病毒M2e与白喉毒素无毒突变体CRM197融合蛋白的抗原性和免疫原性分析;李琼 等;《病毒学报》;20170630;第33卷(第4期);第483-493页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107522777A (zh) | 2017-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107488218B (zh) | 一种多肽、免疫原性偶联物和流感疫苗 | |
CN107074912B (zh) | 流行性感冒病毒疫苗及其用途 | |
CN102807621B (zh) | 包含白喉毒素无毒突变体crm197或其片段的融合蛋白 | |
KR101983989B1 (ko) | 인플루엔자 바이러스 백신 및 이의 용도 | |
US4474757A (en) | Synthetic vaccine and process for producing same | |
AU2014273173B2 (en) | Influenza virus vaccines and uses thereof | |
CN107522777B (zh) | 用于预防或治疗流感病毒的多肽、免疫原性偶联物及用途 | |
NZ556004A (en) | Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein | |
CN111655284B (zh) | 流感病毒疫苗及其用途 | |
CN112512564A (zh) | 铁蛋白蛋白 | |
CN104507496B (zh) | 包含与crm197载体蛋白偶联的hiv gp41肽的免疫原性化合物 | |
Zeng et al. | A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate | |
CN107488217A (zh) | 一种多肽、免疫原性偶联物和流感疫苗 | |
CN113173977A (zh) | 一种双功能抗原、其制备方法及应用 | |
US10597426B2 (en) | Polypeptide compound and preparation method and use thereof | |
US20180244724A1 (en) | Polypeptide compound and preparation method and use thereof | |
Guo et al. | Chimeric virus-like particles of universal antigen epitopes of coronavirus and phage Qβ coat protein trigger the production of neutralizing antibodies | |
Askelöf et al. | Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. | |
NZ205924A (en) | Synthetic polypeptide: fragment of structural capsid protein; vaccine; method for diagnosis | |
CN106279379B (zh) | 一种免疫原HM4-M2e及其制备方法与应用 | |
WO2013049535A2 (en) | Influenza vaccine | |
KR20220082042A (ko) | 인플루엔자 바이러스 백신 및 이의 용도 | |
CN114057850A (zh) | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 | |
Zou et al. | Self-assembly polymerization enhances the immunogenicity of influenza M2e peptide | |
Tan et al. | Inducing Long Lasting B cell and T cell Immunity against Multiple Variants of SARS‐CoV‐2 through Mutant Bacteriophage Qβ–Receptor Binding Domain Conjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: No. 1, No. 1, No. 1, Hua Lan Boulevard a, Henan, Henan Applicant after: Hualan biological vaccine Co.,Ltd. Applicant after: HUALAN GENETIC ENGINEERING Co.,Ltd. Applicant after: HUALAN BIOLOGICAL ENGINEERING Inc. Applicant after: HUALAN BIOLOGICAL ENGINEERING TECHNOLOGY (BEIJING) Co.,Ltd. Address before: No. 1, No. 1, No. 1, Hua Lan Boulevard a, Henan, Henan Applicant before: HUALAN BIOLOGICAL BACTERIN Co.,Ltd. Applicant before: HUALAN GENETIC ENGINEERING Co.,Ltd. Applicant before: HUALAN BIOLOGICAL ENGINEERING Inc. Applicant before: HUALAN BIOLOGICAL ENGINEERING TECHNOLOGY (BEIJING) Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200807 Address after: No. 1, No. 1, No. 1, Hua Lan Boulevard a, Henan, Henan Applicant after: Hualan biological vaccine Co.,Ltd. Address before: No. 1, No. 1, No. 1, Hua Lan Boulevard a, Henan, Henan Applicant before: Hualan biological vaccine Co.,Ltd. Applicant before: HUALAN GENETIC ENGINEERING Co.,Ltd. Applicant before: HUALAN BIOLOGICAL ENGINEERING Inc. Applicant before: HUALAN BIOLOGICAL ENGINEERING TECHNOLOGY (BEIJING) Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |